PEG-MGF
PEGylated MGF — much longer half-life than native MGF, weekly dosing schedule.
- Half-life
- 2.5 d
- Out of system
- ~13 days
- Route
- Subcutaneous
- Level
- Advanced
Levels carry over between doses — every 2–3 days is typical. After the last dose, roughly 97% has cleared in ~13 days (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What PEG-MGF is used for
- PEGylated MGF — much longer half-life, weekly dosing
- Sustained IGF splice-variant signaling
How it's typically used
Research range: 200–500 mcg subcutaneous weekly.
What to watch for
- Same theoretical cancer-growth concern as IGF compounds
- Limited human evidence
- Research-only; sourcing quality varies
About Performance & GH
- What they are
- Growth-hormone secretagogues and related performance compounds. Rather than supplying GH, they push your pituitary to release more of its own in a pulse.
- How they're run
- Subcutaneous injection, most often at night on an empty stomach so the pulse lands with natural sleep-driven GH release.
- What to watch
- Water retention, tingling hands, and hunger swings are the common early signs. Raising GH raises IGF-1 — worth tracking on bloodwork, and a reason to avoid these with any cancer history.
Full guide
PEG-MGF: Tracking a Long-Acting Mechano Growth Factor
What PEG-MGF is, how PEGylation changes the dosing schedule versus regular MGF, and how that changes what you track and when.
Other performance & gh
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.